Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ESLAW
- Price
- 0.04
- Stock movement down
- -0.01 (-14.83%)
- Company name
- Estrella Immunopharma Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- -
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -50.70%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-12
DIVIDENDS
ESLAW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.04 |
| Daily high | 0.04 |
| Daily low | 0.04 |
| Daily Volume | 1K |
| All-time high | 0.56 |
| 1y analyst estimate | - |
| Beta | -0.09 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ESLAW | S&P500 | |
| Current price drop from All-time high | -92.34% | -1.46% |
| Highest price drop | -96.11% | -56.47% |
| Date of highest drop | 25 Jan 2023 | 9 Mar 2009 |
| Avg drop from high | -71.06% | -10.99% |
| Avg time to new high | 56 days | 12 days |
| Max time to new high | 481 days | 1805 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner